Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting.

purposeTumor Treating Fields therapy (TTFields) is an FDA-approved locoregional treatment for patients with newly diagnosed glioblastoma (ndGBM). Previous trial data showed the addition of TTFields to standard TMZ-based therapy to significantly improve overall survival (OS), but real-world data is lacking, particularly with long follow-up duration. Here, we report real-world survival, patterns of progression, and patterns of use for patients for patients with ndGBM treated with or without TTFields.

methodsPatients diagnosed with GBM and treated with standard of care therapy at the Medical College of Wisconsin between March 2015-March 2023 were included. Survival outcomes were assessed and compared across groups who received or did not receive TTFields therapy during maintenance treatment. Patients were followed through March 1, 2024.

resultsA total of 208 patients (TTFields: n = 109; No-TTFields: n = 99) were included for analysis. Baseline characteristics were consistent across groups. Median OS and PFS were significantly improved for the TTFields group vs. No-TTFields group (median OS: 21.7 vs. 17.7 months, p = 0.029; median PFS: 12.4 vs. 9.6 months, p = 0.047). Patients treated with TTFields exhibited a higher rate of non-local progression vs. No-TTFields group. Median OS and PFS were each significantly longer for the ≥ 75% usage group compared with < 75% via matched analysis.

conclusionThe results of this study reveal an association between TTFields use and long-term survival benefit, consistent with pivotal trial findings. TTFields use is associated with a higher incidence of non-local patterns of progression, and TTFields device usage ≥ 75% is associated with increased progression-free and long-term survival.